Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Hymecromone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 2/20 | 0.87 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.87 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.87 |
| ▸ | CA9 | Q16790 | 7/20 | 0.87 |
| ▸ | HSD17B3 | P37058 | 6/20 | 0.87 |
| ▸ | CA12 | O43570 | 5/20 | 0.87 |
| ▸ | HPGD | P15428 | 4/20 | 0.87 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.87 |
| ▸ | GAA | P10253 | 4/20 | 0.87 |
| ▸ | GLA | P06280 | 3/20 | 0.87 |
| ▸ | CASP1 | P29466 | 2/20 | 0.87 |
| ▸ | CASP7 | P55210 | 2/20 | 0.87 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.87 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.87 |
| ▸ | LMNA | P02545 | 1/20 | 0.87 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.87 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.87 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.87 |
| ▸ | KDR | P35968 | 1/20 | 0.87 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hymecromone SCHEMBL15418604 | 0.98 | KDM4E (0.84) | KDM4EALDH1A1CA9HSD17B3CA12 | |
| Hymecromone SCHEMBL10850194 | 0.95 | ALDH1A1 (0.84) | KDM4EALDH1A1CA9HSD17B3CA12 | |
| Hymecromone SCHEMBL2357040 | 0.93 | HSD17B3 (1.00) | KDM4EALDH1A1CA9HSD17B3CA12 | |
| Hymecromone SCHEMBL24150 | 0.93 | HSD17B3 (1.00) | KDM4EALDH1A1CA9HSD17B3CA12 | |
| Hymecromone SCHEMBL29624431 | 0.93 | HSD17B3 (1.00) | KDM4EALDH1A1CA9HSD17B3CA12 | |
| Hymecromone SCHEMBL29364837 | 0.93 | HSD17B3 (1.00) | KDM4EALDH1A1CA9HSD17B3CA12 | |
| Hymecromone SCHEMBL31014 | 0.92 | HSD17B3 (0.96) | KDM4EALDH1A1CA9HSD17B3CA12 | |
| Hymecromone SCHEMBL27924142 | 0.92 | HSD17B3 (0.96) | KDM4EALDH1A1CA9HSD17B3CA12 | |
| Hymecromone SCHEMBL15418603 | 0.91 | KDM4E (0.82) | KDM4EALDH1A1CA9HSD17B3CA12 | |
| Hymecromone SCHEMBL27728511 | 0.90 | HSD17B3 (0.93) | KDM4EALDH1A1CA9HSD17B3CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113646427-A | Engineered arylsulfate-dependent enzymes | 奥普蒂姆维亚有限公司 | 2021-11-12 | — | — | CN | claimed |
| US-20210231645-A1 | METHODS AND COMPOSITIONS FOR INVESTIGATING MULTIPLE DRUG-DRUG TRANSPORTER INTERACTIONS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2021-07-29 | — | — | US | claimed |
| WO-2021119326-A1 | METHODS AND COMPOSITIONS FOR INVESTIGATING MULTIPLE DRUG-DRUG TRANSPORTER INTERACTIONS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-06-17 | — | — | WO | claimed |
| US-20200101042-A1 | 4-METHYLUMBELLIFERONE TREATMENT FOR IMMUNE MODULATION | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON (US) | 2020-04-02 | — | — | US | claimed |
| WO-2019165319-A1 | THE USE OF 4-METHYLUMBELLIFERONE TO PREVENT IMMUNE REJECTION IN CASES OF TISSUE TRANSPLANTATION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-08-29 | — | — | WO | claimed |
| US-10285976-B2 | 4-methylumbelliferone treatment for immune modulation | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2019-05-14 | — | — | US | claimed |
| US-20160184262-A1 | 4-METHYLUMBELLIFERONE TREATMENT FOR IMMUNE MODULATION | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON (US) | 2016-06-30 | — | — | US | claimed |
| EP-3033416-A2 | 4-METHYLUMBELLIFERONE TREATMENT FOR IMMUNE MODULATION | Benaroya Research Institute at Virginia Mason (US) | 2016-06-22 | — | — | EP | claimed |
| WO-2015023691-A2 | 4-METHYLUMBELLIFERONE TREATMENT FOR IMMUNE MODULATION | BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON (US) | 2015-02-19 | — | — | WO | claimed |
| US-20090203056-A1 | KIT FOR DIAGNOSIS OF CANCER | BEIJING ACCB BIOTECH LTD. (CN) | 2009-08-13 | — | — | US | claimed |
| EP-2085483-A1 | TEST KIT FOR DETECTING CANCERS | Beijing Accb Biotech Ltd. (CN) | 2009-08-05 | — | — | EP | claimed |
| CN-101183075-A | Cancer detection reagent kit | BEIJING YAKANGBO BIOTECHNOLOGY (CN) | 2008-05-21 | — | — | CN | claimed |
| US-12031977-B2 | Ex vivo system for determining multiple drug-drug transporter interactions and methods of use thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-07-09 | — | — | US | disclosed |
| CN-117202940-A | Treatment of mucopolysaccharidosis II with recombinant human iduronate-2-sulfatase (IDS) | 再生生物股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-116964201-A | Compositions, devices and methods for treating MPS VI diseases | 西吉隆医疗股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-116397000-A | Composite slow-release micro-nano particles, and synthesis method and application thereof | 中国科学院微生物研究所 | 2023-07-07 | — | — | CN | disclosed |
| US-20070053869-A1 | Formulation and method for enhancement of gastrointestinal absorption of pharmaceutical agents | WARNER-LAMBERT COMPANY LLC | 2007-03-08 | — | — | US | disclosed |
| WO-2007027560-A2 | FORMULATION AND METHOD FOR ENHANCEMENT OF GASTROINTESTINAL ABSORPTION OF PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20050014215-A1 | Method and medium for the detecting/identifying microorganisms with esterase and/or r osidase and/or peptidase and/or sulfatase and/or phosphatase activity | BIO MERIEUX (FR) | 2005-01-20 | — | — | US | disclosed |
| US-4659657-A | Chromogenic and fluorogenic esters for photometric or fluorimetric determination of phosphatases or sulphatases | BAYER AKTIENGESELLSCHAFT (DE) | 1987-04-21 | — | — | US | disclosed |